Accent Therapeutics
Founded 2017 · 31 employees on LinkedIn · 14 known investors
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients. It operates in oncology-focused drug discovery and development.
Investors · 14
Atlas VentureCambridge · $500K – $1M
Droia VenturesLeuven · $540K
EcoR1 CapitalSan Francisco
GV (Google Ventures)Mountain View · $250K – $50M
The Column GroupSan Francisco · $30M
JJDCreportedNew Brunswick · $500K – $5M
Johnson & Johnson Innovation – JJDCreportedNew Brunswick
Mirae Asset Venture Investmentreported$594K – $54M
Also in the syndicate · 6
AbbVie VenturesBristol Myers SquibbMirae Asset CapitalMirae Asset Capital Life ScienceleadThe Mark Foundation for Cancer ResearchTimefolio Capital
Funding
SEC filings, press & company announcements$75M disclosed across 1 round · 2024
- $75MSeries CJan 2024 · 3 sources
Mirae Asset Capital Life Science (lead), AbbVie Ventures, Atlas Venture, Bristol Myers Squibb, Droia Ventures, EcoR1 Capital, GV, JJDC, Johnson & Johnson Innovation – JJDC, Inc., Mirae Asset Capital, Mirae Asset Venture Investment, The Column Group, The Mark Foundation for Cancer Research, Timefolio Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Accent Therapeutics do?
- Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients. It operates in oncology-focused drug discovery and development.
- Who are Accent Therapeutics's investors?
- Accent Therapeutics's investors include Atlas Venture, Droia Ventures, EcoR1 Capital, GV (Google Ventures), The Column Group, JJDC, Johnson & Johnson Innovation – JJDC, Mirae Asset Venture Investment.
- How much funding has Accent Therapeutics raised?
- Accent Therapeutics has disclosed $75M raised across 1 round.